Literature DB >> 12675275

Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.

Kizuku Kuramoto1, Shuichi Ichikawa, Aizan Hirai, Shigeto Kanada, Tetsu Nakachi, Toshio Ogihara.   

Abstract

We objected: 1) To compare the effects of azelnidipine and amlodipine on 24-h blood pressure; 2) To monitor the plasma concentration vs. the time profile in order to assess the association between pharmacokinetics and hypotensive activity after administration of either drug for 6 weeks. Blood pressure and pulse rate were measured by 24-h monitoring with a portable automatic monitor in a randomized double-blind study of 46 patients with essential hypertension. Azelnidipine 16 mg (23 patients) or amlodipine 5 mg (23 patients) was administered once daily for 6 weeks. Pharmacokinetics were analyzed after the last dose was taken. Both drugs showed similar effects on the office blood pressure and pulse rate. During 24-h monitoring, both drugs caused a decrease in systolic blood pressure of 13 mmHg and had a similar hypotensive profile during the daytime period (07:00-21:30). The pulse rate decreased by 2 beats/min in the azelnidipine group, whereas it significantly increased by 4 beats/min in the amlodipine group. Similar trends in the blood pressure and pulse rate were observed during the nighttime (22:00-6:30) and over 24 h. Excessive blood pressure reduction during the nighttime was not seen in either group. The pharmacokinetic results indicated that the plasma half-life (t1/2) of amlodipine was 38.5 +/- 19.8 h and that of azelnidipine was 8.68 +/- 1.33 h. Despite this difference in pharmacokinetics, the hypotensive effects of amlodipine and azelnidipine were similar throughout the 24-h administration period.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675275     DOI: 10.1291/hypres.26.201

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  23 in total

1.  Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.

Authors:  Yumi Koike; Tetsuya Kawabe; Kanami Nishihara; Naomi Iwane; Takuzo Hano
Journal:  Hypertens Res       Date:  2016-07-21       Impact factor: 3.872

2.  Resting heart rate and the risk of developing impaired fasting glucose and diabetes: the Kailuan prospective study.

Authors:  Liang Wang; Liufu Cui; Yanxue Wang; Anand Vaidya; Shuohua Chen; Caifeng Zhang; Ying Zhu; Dongqing Li; Frank B Hu; Shouling Wu; Xiang Gao
Journal:  Int J Epidemiol       Date:  2015-05-22       Impact factor: 7.196

3.  The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle.

Authors:  H-L Zhu; T Tomoda; M Aishima; Y Ito; N Teramoto
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

4.  Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.

Authors:  T Ohyama; K Sato; K Kishimoto; Y Yamazaki; N Horiguchi; T Ichikawa; S Kakizaki; H Takagi; T Izumi; M Mori
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 5.  Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy.

Authors:  Paolo Palatini; Athanase Benetos; Stevo Julius
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Azelnidipine.

Authors:  Keri Wellington; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

8.  Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.

Authors:  Takeshi Takami; Yoshihiko Saito
Journal:  Vasc Health Risk Manag       Date:  2011-06-17

9.  Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension.

Authors:  Qi Chen; Qi-Fang Huang; Yuan-Yuan Kang; Shao-Kun Xu; Chang-Yuan Liu; Yan Li; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-30       Impact factor: 3.738

10.  Inhibitory effects of azelnidipine tablets on morning hypertension.

Authors:  Kazuomi Kario; Yuki Sato; Masayuki Shirayama; Megumi Takahashi; Kazuhito Shiosakai; Katsutoshi Hiramatsu; Masahiro Komiya; Kazuyuki Shimada
Journal:  Drugs R D       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.